2014
HER2 in Breast Cancer
Krishnamurti U, Silverman J. HER2 in Breast Cancer. Advances In Anatomic Pathology 2014, 21: 100-107. PMID: 24508693, DOI: 10.1097/pap.0000000000000015.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsDrug DesignFemaleGene AmplificationHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMolecular Diagnostic TechniquesMolecular Targeted TherapyPrecision MedicinePredictive Value of TestsProtein Kinase InhibitorsReceptor, ErbB-2Signal TransductionTreatment OutcomeUp-RegulationConceptsBreast cancerHER2 receptorTime of diagnosisInvasive breast cancerHER2 receptor overexpressionValuable therapeutic targetHER2 biologyASCO guidelinesHER2 statusHER2 amplificationHER2 testingHER2 oncogeneTherapeutic targetReceptor overexpressionHER2CancerMembrane tyrosine kinaseTumor developmentCell proliferationCurrent standardReceptorsTyrosine kinaseChromosome 17q12RecurrenceTherapy
1996
Integrin-mediated interactions between primary/T-sv40 immortalized human glomerular epithelial cells and type IV collagen.
Krishnamurti U, Chen Y, Michael A, Kim Y, Fan W, Wieslander J, Brunmark C, Rondeau E, Sraer J, Delarue F, Tsilibary E. Integrin-mediated interactions between primary/T-sv40 immortalized human glomerular epithelial cells and type IV collagen. Laboratory Investigation 1996, 74: 650-7. PMID: 8600316.Peer-Reviewed Original ResearchConceptsHuman glomerular epithelial cellsGlomerular basement membraneGlomerular epithelial cellsType IV collagenExpression of integrinsEpithelial cellsVisceral glomerular epithelial cellsIV collagenSurface receptorsFlow cytometric analysisNoncollagenous NC1 domainFlow cytometryCytometric analysisCell surface receptorsMonoclonal antibodiesNC1 domain